RBC Capital analyst Brian Abrahams maintained a Hold rating on 89bio (ETNB – Research Report) yesterday and set a price target of $12.00.

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...

The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated ...

On October 17, 2024, Suvretta Capital Management, LLC executed a significant transaction involving the shares of 89bio Inc (NASDAQ ... the grant of non-qualified stock options to purchase an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period ...

Making long-term predictions for individual stock prices is very difficult. Past performance doesn't guarantee future results. Whether a stock has done well or fared poorly, the tide can shift ...

Amazon stock increased over 40% year over year as of Oct. 28, 2024. But it is not guaranteed to continue rising at this pace. Some predictions of Amazon stock suggest it could reach about $215 per ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tesla earnings are due amid Model Y refresh buzz. TSLA stock has tumbled in October on Q3 deliveries and the robotaxi event. BYD stock is back in a buy zone. We recently looked at Goldman Sachs’ ...